Immuno Oncology Assays Market Surpasses the growth during 2019-2027
Immuno Oncology Assays |
Next-generation sequencing applications include
immuno-oncology Assays. For real-time measurements or continuous analysis,
immuno oncology tests assist to preserve cell shape as well as cell health. T
cell assays, Tumor killing assays, Tumor cell assays, Natural killer cell
assays, Macrophage assays, and Dendritic cell assays are among the immuno
oncology Assays available.
Immuno Oncology Assays
Market Drivers-
During the projected period, new product releases are likely to drive the immuno oncology assays market forward. For example, Roche Diagnostics released the VENTANA HER2 Dual ISH DNA Probe Cocktail test in April 2019 for detecting the biomarker human epidermal growth factor receptor 2 (HER2) in breast and gastric malignancies.
In addition, leading market players are focusing on releasing innovative immuno oncology assays, which is projected to propel the immune oncology assays market forward. For example, in August 2018, Thermo Fisher Scientific reported that the Thermo Oncomine Tumor Mutation Load Assay, a new technique in immuno-oncology therapy, had been validated for clinical trials. As a result, it is predicted to become a quick and reliable predictor of patient satisfaction and response to treatment.
Immuno Oncology Assays Market Restraints-
The market's expansion is projected to be hampered by increasing hurdles in large-scale manufacture of immuno oncology assays. Specialist teams and skilled investigators are required for the development of immuno-oncology tests. Additionally, the cost of producing immuno-oncology tests is high and time-consuming, which is projected to limit the immuno-oncology market's growth.
Impact of Covid-19 on
Immuno-oncology Assays Market-
Cancer patients have emerged as one of the pandemic's most
severely afflicted patient groups. COVID-19 has had a significant influence on
the number of patients who are screened, diagnosed, and treated for cancer. Due
to the rising number of COVID-19 patients being admitted to hospitals, several
hospitals and departments, including cancer clinics, have been re-profiled to
treat COVID-19 patients. As a result, numerous diagnostic and treatment
operations were cancelled or postponed throughout the world, according to one
research, including as many as 2.3 million cancer surgeries. Cancer death rates
are predicted to rise as a result of delayed detection and treatment of cancer
patients due to lockdown-related constraints.
COVID-19 had an effect on a number of patients who had
cancer. Further study is being conducted in this area in order to better
understand the dynamics of infection, which is likely to advance the cancer
research sector. The change in demand for COVID-19 and oncology research has
opened up a lot of opportunities for testing solutions such assays and
profiling panel testing kits. Demand for immuno-oncology tests and instruments
is likely to rise as a result of this.
Explore more reports
related to Biotechnology Industry- https://bit.ly/3vDToMH
Comments
Post a Comment